Allogeneic human fibroblasts

Allogeneic human fibroblasts are a cellular therapeutic agent derived from donor tissue, most commonly neonatal foreskin, and are utilized in regenerative medicine to treat chronic wounds and mucogingival conditions (FDA, 2012). These cells function as biological factories, secreting a complex array of growth factors such as Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF), as well as cytokines and extracellular matrix proteins like collagen and fibronectin that facilitate the natural healing process (Greaves et al., 2013). In clinical applications, they are often delivered via a scaffold or as part of a bilayered skin substitute to provide both structural support and biochemical signaling to the recipient's tissue (Eaglstein et al., 1999). While they are not a single molecular target, their therapeutic efficacy relies on their ability to modulate the wound microenvironment, stimulate angiogenesis, and promote the migration of host keratinocytes (Haugh et al., 2017). Key products utilizing this technology include Gintuit for oral applications and Dermagraft for diabetic foot ulcers (Marston et al., 2003). Safety profiles are generally favorable due to the low immunogenicity of fibroblasts, though rigorous donor screening is essential to mitigate the risk of pathogen transmission (Zaulyanov & Kirsner, 2007).

Other names

Allogeneic dermal fibroblastsHuman allogeneic fibroblastsDonor-derived fibroblastsAllogeneic cultured dermal fibroblasts

Secretion of a complex array of growth factors, cytokines, and extracellular matrix proteins to modulate the wound microenvironment and stimulate host tissue regeneration.